FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella
Abstract
Share and Cite
Tian, T.; Zhu, Y.; Shang, K.; Shi, H.; Xu, R.; Li, M.; Pu, F.; Kuang, J.; Ding, J.; Zhang, F. FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella. Vaccines 2025, 13, 567. https://doi.org/10.3390/vaccines13060567
Tian T, Zhu Y, Shang K, Shi H, Xu R, Li M, Pu F, Kuang J, Ding J, Zhang F. FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella. Vaccines. 2025; 13(6):567. https://doi.org/10.3390/vaccines13060567
Chicago/Turabian StyleTian, Tingting, Yuejie Zhu, Kaiyu Shang, Huidong Shi, Ruixue Xu, Mingzhe Li, Fuling Pu, Junyu Kuang, Jianbing Ding, and Fengbo Zhang. 2025. "FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella" Vaccines 13, no. 6: 567. https://doi.org/10.3390/vaccines13060567
APA StyleTian, T., Zhu, Y., Shang, K., Shi, H., Xu, R., Li, M., Pu, F., Kuang, J., Ding, J., & Zhang, F. (2025). FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against Brucella. Vaccines, 13(6), 567. https://doi.org/10.3390/vaccines13060567